DNB Asset Management AS Makes New $558,000 Investment in Rhythm Pharmaceuticals, Inc. $RYTM

DNB Asset Management AS acquired a new stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) during the third quarter, HoldingsChannel reports. The fund acquired 5,528 shares of the company’s stock, valued at approximately $558,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in RYTM. Nisa Investment Advisors LLC lifted its holdings in Rhythm Pharmaceuticals by 956.9% in the third quarter. Nisa Investment Advisors LLC now owns 13,254 shares of the company’s stock valued at $1,339,000 after acquiring an additional 12,000 shares during the period. EFG Asset Management North America Corp. purchased a new stake in shares of Rhythm Pharmaceuticals during the 3rd quarter valued at about $2,047,000. Penserra Capital Management LLC bought a new position in shares of Rhythm Pharmaceuticals in the 3rd quarter worth approximately $3,073,000. Hillsdale Investment Management Inc. bought a new position in shares of Rhythm Pharmaceuticals in the 3rd quarter worth approximately $4,302,000. Finally, Norges Bank bought a new stake in Rhythm Pharmaceuticals during the second quarter valued at approximately $13,105,000.

Rhythm Pharmaceuticals News Roundup

Here are the key news stories impacting Rhythm Pharmaceuticals this week:

• Positive Sentiment: Canaccord Genuity raised its price target to $140, signaling stronger upside expectations from that shop and likely supporting buying interest. Canaccord raises PT to $140
• Neutral Sentiment: H.C. Wainwright reaffirmed a “Buy” stance and set a $110 target, keeping institutional support for the stock even after adjusting assumptions; that helps sentiment but is less bullish than Canaccord’s view. H.C. Wainwright price target cut to $110
• Negative Sentiment: H.C. Wainwright cut near-term EPS forecasts sharply — trimming FY2026 and multiple quarterly estimates and pushing meaningful profitability into 2027 (they still model positive EPS in FY2027). Those downgraded near-term earnings projections increase execution risk and explain some downward pressure/volatility despite the maintained Buy rating.

Insider Activity

In other news, CFO Hunter C. Smith sold 4,385 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $101.26, for a total transaction of $444,025.10. Following the transaction, the chief financial officer owned 110,512 shares of the company’s stock, valued at approximately $11,190,445.12. This represents a 3.82% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Pamela J. Cramer sold 3,350 shares of the company’s stock in a transaction on Thursday, December 11th. The shares were sold at an average price of $111.00, for a total value of $371,850.00. Following the completion of the transaction, the insider directly owned 20,814 shares in the company, valued at $2,310,354. This trade represents a 13.86% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 25,003 shares of company stock worth $2,589,015 over the last quarter. 6.10% of the stock is currently owned by insiders.

Rhythm Pharmaceuticals Price Performance

NASDAQ:RYTM opened at $91.00 on Thursday. The company has a market cap of $6.21 billion, a price-to-earnings ratio of -29.26 and a beta of 2.06. Rhythm Pharmaceuticals, Inc. has a 1 year low of $45.90 and a 1 year high of $122.20. The stock’s 50 day simple moving average is $102.65 and its two-hundred day simple moving average is $103.42.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last released its quarterly earnings data on Thursday, February 26th. The company reported ($0.73) EPS for the quarter, beating the consensus estimate of ($0.79) by $0.06. The business had revenue of $57.25 million during the quarter, compared to analyst estimates of $56.16 million. Rhythm Pharmaceuticals had a negative net margin of 103.57% and a negative return on equity of 266.56%. Rhythm Pharmaceuticals’s quarterly revenue was up 36.9% compared to the same quarter last year. During the same quarter last year, the business earned ($0.72) earnings per share. As a group, analysts anticipate that Rhythm Pharmaceuticals, Inc. will post -4.32 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on RYTM shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rhythm Pharmaceuticals in a research note on Thursday, January 22nd. Oppenheimer lowered Rhythm Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Wednesday, November 5th. TD Cowen reaffirmed a “buy” rating on shares of Rhythm Pharmaceuticals in a research note on Thursday, December 11th. UBS Group reiterated a “buy” rating on shares of Rhythm Pharmaceuticals in a research note on Wednesday, December 17th. Finally, HC Wainwright decreased their target price on shares of Rhythm Pharmaceuticals from $125.00 to $110.00 and set a “buy” rating on the stock in a research note on Monday. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $132.07.

Rhythm Pharmaceuticals Profile

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.